Loading...
•
Mar 31, 2024
United Therapeutics Q1 2024 Earnings Report
United Therapeutics reported record revenue and double-digit year-over-year revenue growth.
Key Takeaways
United Therapeutics reported a 34% increase in total revenues to $677.7 million for Q1 2024, compared to $506.9 million in Q1 2023. Net income increased by 27% to $306.6 million. The company also implemented a $1 billion accelerated share repurchase program.
Total revenues grew by 34% year-over-year to $677.7 million.
Net income increased by 27% to $306.6 million.
Tyvaso revenues increased by 56% to $372.5 million.
Implemented a $1 billion accelerated share repurchase program.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
United Therapeutics did not provide specific forward guidance in this earnings report. The report highlights the company's revenue growth, clinical catalysts, and potential for organ manufacturing.
Positive Outlook
- Solid and growing commercial foundation.
- Near-term clinical catalysts.
- Potential to provide an unlimited supply of tolerable, transplantable organs.
- Solid balance sheet.
- Strong cash flow potential.
Challenges Ahead
- Potential competition emerging this year.
- Risks and uncertainties described in periodic reports filed with the Securities and Exchange Commission.
- Impact of potential competition on near-term and long-term potential.
- No specific financial guidance provided.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...